search
Back to results

Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2 (PrEliMS2)

Primary Purpose

Multiple Sclerosis

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Acceptance and Commitment Therapy
Sponsored by
University of Nottingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis focused on measuring Acceptance and Commitment Therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged 18 and/or over.
  2. Received a new diagnosis of MS within the last six months, confirmed by a Consultant Neurologist.
  3. Scores ≥8 on the GAD-7 and/or ≥10 on the PHQ-9.

Exclusion Criteria:

  1. Unable or willing to give informed consent.
  2. Individuals currently receiving psychological therapy, to ensure any change cannot be attributed to another intervention.
  3. Individuals who have had a prior diagnosis of psychological distress, e.g., Depression or Anxiety Disorder, to ensure participants are as homogenous as possible. The intervention is aimed at distress specifically related to receiving an MS diagnosis.
  4. Unable to speak and read English (as all measure used have been standardised and validated in English, and the workbook is only available in English).
  5. Unable to use/do not have access to a telephone or a computer with internet connection

Sites / Locations

  • Queens Medical Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PrEliMS Intervention

Arm Description

We will ask participants to complete the anxiety/depression questionnaires and visual analogue scales once a week throughout the participants involvement in the study (estimated to be 9 weeks). The baseline will be established over a period of the first three weeks (before participants start the intervention). Participants will also be asked to complete a second set of questionnaires (secondary measures) before starting the intervention, to assess quality of life, stress, the impact of MS, MS-related self-efficacy and fatigue. The procedure will then repeated with newly recruited participants, and the newly refined workbook will be used. Participants within this phase will also be invited to feedback interviews a week after completion of the intervention.

Outcomes

Primary Outcome Measures

Patient Health Questionnaire - 9 (PHQ-9)
Change in the level of depression symptoms. Higher scores indicate a worse outcome, total scores range from 0-27, scale values range from 0-3.
Generalised Anxiety Disorder - 7 (GAD-7)
Change in the level of anxiety symptoms. Higher scores indicate a worse outcome, total scores range from 0-21, scale values range from 0-3.
Visual Analogue Scale
Change in the level of psychological distress related to receiving an MS diagnosis and confidence in managing day to day. Scale ranges from 0-10.
Comprehensive Assessment of Acceptance and Commitment Therapy processes (CompACT-8; Morris, 2019; Dawson & Golijani-Moghaddam, 2020).
Scale to measure change in ACT-process of psychological flexibility. Higher scores indicate a better outcome, total scores range from 0-48, scale values range from 0-6.

Secondary Outcome Measures

Health-related quality of life
EQ-5D-5L (Herdman et al., 2011). Five scaled questions assessing five domains of quality of life (mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each response corresponds to a 1-digit number. The total responses are combined into a 5-digit number to represent health state, e.g., 11111 represents no problems in health state. These are then converted to an index score; higher scores indicate greater health related quality of life.
Perceived levels of stress
Perceived Stress Scale 4 (PSS4; Cohen et al., 1983). Total scores range from 0-40, with higher scores indicating greater perceived level of stress. Ten scale questions, scaled values range from 0-4.
Perceived psychological impact of MS
Multiple Sclerosis Impact Scale-Psychological Subscale (MSIS-29-PSYCH; Hobart et al., 2001; Ramp et al., 2009). Total scores range from 0-45, with higher scores indicating greater perceived psychological impact of MS. Nine scaled questions with scale values ranging from 1-5.
Self efficacy in the context of MS
Multiple Sclerosis Self Efficacy Scale (MSSES; Rigby et al., 2003). Total score ranges from 0-84, with higher scores indicating greater level of self-efficacy. 14 scaled questions with values ranging from 1-6.
Levels of fatigue
Modified Impact Fatigue Scale; abbreviated version (MFIS-5; Fisk et al., 1994; Fischer et al., 1999). Total score ranges from 0-20; higher scores indicate greater impact of fatigue. Scale scores range from 0-4 with 5 scaled questions.

Full Information

First Posted
January 10, 2022
Last Updated
September 7, 2023
Sponsor
University of Nottingham
search

1. Study Identification

Unique Protocol Identification Number
NCT05225012
Brief Title
Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2
Acronym
PrEliMS2
Official Title
Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
August 12, 2022 (Actual)
Primary Completion Date
April 28, 2023 (Actual)
Study Completion Date
June 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Nottingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Emotional support following Multiple Sclerosis (MS) diagnosis is not part of the current service provision. However, research has identified a need for this as poor adjustment to diagnosis has been linked to higher levels of psychological distress. A previous study, named 'Providing Emotional Support Around the Point of MS Diagnosis' (PrEliMS), explored how best to provide support. People with MS completed a self-help workbook, alongside receiving support from MS nurses. The workbook is based on a psychological therapy called Acceptance and Commitment Therapy and was developed through focus groups of people with MS, relevant stakeholders, and clinical expertise. In this study, issues were found with parts of the workbook content and delivery. Nurses found it difficult to facilitate this alongside their usual MS Nurse care and felt psychological distress was not within their remit. In this study, the investigators will explore how effective the PrEliMS workbook is at reducing distress from MS diagnosis, when delivered by a Psychology Practitioner (Trainee Clinical Psychologist) compare delivery by a Psychology Practitioner with the data from the Nurse delivered PrEliMS trial to explore which is more effective revise the workbook based on feedback from participants and what was learnt from the PrEliMS feasibility trial, to improve patient experience. The investigators will recruit seven people from an MS clinic who have received an MS diagnosis in the last 6-months and consent to taking part. Participants will meet with a Psychology Practitioner (over the phone or online) once a week for four weeks, alongside completing the workbook. The investigators will also ask participants to complete questionnaires to examine their levels of psychological distress. Interviews will then be conducted to get feedback for refining the workbook. The procedure will then be repeated with the refined workbook and seven newly recruited participants. The overall study will last a year

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
Acceptance and Commitment Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Case series design
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PrEliMS Intervention
Arm Type
Experimental
Arm Description
We will ask participants to complete the anxiety/depression questionnaires and visual analogue scales once a week throughout the participants involvement in the study (estimated to be 9 weeks). The baseline will be established over a period of the first three weeks (before participants start the intervention). Participants will also be asked to complete a second set of questionnaires (secondary measures) before starting the intervention, to assess quality of life, stress, the impact of MS, MS-related self-efficacy and fatigue. The procedure will then repeated with newly recruited participants, and the newly refined workbook will be used. Participants within this phase will also be invited to feedback interviews a week after completion of the intervention.
Intervention Type
Other
Intervention Name(s)
Acceptance and Commitment Therapy
Intervention Description
Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
Primary Outcome Measure Information:
Title
Patient Health Questionnaire - 9 (PHQ-9)
Description
Change in the level of depression symptoms. Higher scores indicate a worse outcome, total scores range from 0-27, scale values range from 0-3.
Time Frame
Once a week from baseline to 1-week follow-up
Title
Generalised Anxiety Disorder - 7 (GAD-7)
Description
Change in the level of anxiety symptoms. Higher scores indicate a worse outcome, total scores range from 0-21, scale values range from 0-3.
Time Frame
Once a week from baseline to 1-week follow-up
Title
Visual Analogue Scale
Description
Change in the level of psychological distress related to receiving an MS diagnosis and confidence in managing day to day. Scale ranges from 0-10.
Time Frame
Once a week from baseline to 1-week follow-up
Title
Comprehensive Assessment of Acceptance and Commitment Therapy processes (CompACT-8; Morris, 2019; Dawson & Golijani-Moghaddam, 2020).
Description
Scale to measure change in ACT-process of psychological flexibility. Higher scores indicate a better outcome, total scores range from 0-48, scale values range from 0-6.
Time Frame
Once a week from baseline to 1-week follow-up
Secondary Outcome Measure Information:
Title
Health-related quality of life
Description
EQ-5D-5L (Herdman et al., 2011). Five scaled questions assessing five domains of quality of life (mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each response corresponds to a 1-digit number. The total responses are combined into a 5-digit number to represent health state, e.g., 11111 represents no problems in health state. These are then converted to an index score; higher scores indicate greater health related quality of life.
Time Frame
Baseline and 1-week follow-up
Title
Perceived levels of stress
Description
Perceived Stress Scale 4 (PSS4; Cohen et al., 1983). Total scores range from 0-40, with higher scores indicating greater perceived level of stress. Ten scale questions, scaled values range from 0-4.
Time Frame
Baseline and 1-week follow-up
Title
Perceived psychological impact of MS
Description
Multiple Sclerosis Impact Scale-Psychological Subscale (MSIS-29-PSYCH; Hobart et al., 2001; Ramp et al., 2009). Total scores range from 0-45, with higher scores indicating greater perceived psychological impact of MS. Nine scaled questions with scale values ranging from 1-5.
Time Frame
Baseline and 1-week follow-up
Title
Self efficacy in the context of MS
Description
Multiple Sclerosis Self Efficacy Scale (MSSES; Rigby et al., 2003). Total score ranges from 0-84, with higher scores indicating greater level of self-efficacy. 14 scaled questions with values ranging from 1-6.
Time Frame
Baseline and 1-week follow-up
Title
Levels of fatigue
Description
Modified Impact Fatigue Scale; abbreviated version (MFIS-5; Fisk et al., 1994; Fischer et al., 1999). Total score ranges from 0-20; higher scores indicate greater impact of fatigue. Scale scores range from 0-4 with 5 scaled questions.
Time Frame
Baseline and 1-week follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 and/or over. Received a new diagnosis of MS within the last six months, confirmed by a Consultant Neurologist. Scores ≥8 on the GAD-7 and/or ≥10 on the PHQ-9. Exclusion Criteria: Unable or willing to give informed consent. Individuals currently receiving psychological therapy, to ensure any change cannot be attributed to another intervention. Individuals who have had a prior diagnosis of psychological distress, e.g., Depression or Anxiety Disorder, to ensure participants are as homogenous as possible. The intervention is aimed at distress specifically related to receiving an MS diagnosis. Unable to speak and read English (as all measure used have been standardised and validated in English, and the workbook is only available in English). Unable to use/do not have access to a telephone or a computer with internet connection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nima Moghaddam, DClinPsy
Organizational Affiliation
University of Lincoln
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Nikos Evangelou, DPhil
Organizational Affiliation
University of Nottingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queens Medical Hospital
City
Nottingham
ZIP/Postal Code
NG7 2UH
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2

We'll reach out to this number within 24 hrs